Erin Strahan, PA
Physician Assistant · Sheridan, WYNPI 1396995890
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 134 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AstraZeneca at 31.4% of the total. 2025 is the largest year on record at $748, 3.5 times the $217 reported in 2021. Among physician assistant clinicians in WY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 134 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$837
- Lilly USA, LLC$340
- GSK$300
- AbbVie$225
- Novo Nordisk$153
- Astellas Pharma US Inc$114
- plus $695 from 18 others
What the payments were for
- Food & beverage$2,664100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $837 |
| Lilly USA, LLC | 22 | $340 |
| GSK | 14 | $300 |
| AbbVie | 9 | $225 |
| Novo Nordisk | 8 | $153 |
| Astellas Pharma US Inc | 4 | $114 |
| Abbott | 6 | $108 |
| Amgen | 5 | $82 |
| Bayer | 4 | $68 |
| Novartis | 3 | $60 |
| Insmed, Inc. | 2 | $53 |
| Organon | 3 | $38 |
| Exact Sciences | 2 | $34 |
| Pfizer | 2 | $33 |
| Merck | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 1 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Boehringer Ingelheim | 1 | $27 |
| IBSA Pharma Inc. | 1 | $24 |
| Grifols USA, LLC | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,664 in reported general payments places this provider in the 90th percentile of 203 physician assistant providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 85 | $104,513 |
| OzempicSemaglutide | 64 | $68,759 |
| EliquisApixaban | 46 | $60,580 |
| TrulicityDulaglutide | 24 | $35,296 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $31,315 |
| XareltoRivaroxaban | 18 | $29,612 |
| FarxigaDapagliflozin Propanediol | 28 | $21,328 |
| JardianceEmpagliflozin | 18 | $18,221 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $17,830 |
| JanuviaSitagliptin Phosphate | 14 | $14,288 |
| MyrbetriqMirabegron | 13 | $11,164 |
| LyricaPregabalin | 12 | $10,623 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $8,278 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $6,024 |
| DuleraMometasone/Formoterol | 13 | $4,875 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $340 | $139,809109 claims |
| PfizerEliquis, Lyrica | $33 | $71,20458 claims |
| Novo NordiskOzempic | $153 | $68,75964 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $837 | $52,64364 claims |
| MerckJanuvia, Dulera | $31 | $19,16227 claims |
| Boehringer IngelheimJardiance | $27 | $18,22118 claims |
| GSKTrelegy Ellipta | $300 | $17,83021 claims |
| Astellas Pharma US IncMyrbetriq | $114 | $11,16413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 203 physician assistant providers in Wyoming.
Other physician assistant in Sheridan
- Tanja SloanSheridan$6K
- Jennifer GraslieSheridan$4K
- Wendy PriceSheridan$2K
- Sarah CoulterSheridan$1K
- Joann RamseyCasper$5K
- Shawn RockeyRock Springs$4K
- Laurie JohnsonCasper$4K
- Robyn MorrisonCasper$4K
- Chloe LowneyAfton$4K
- Alison WatkinsCheyenne$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.